HIV Prevention

Infectious Diseases
5
Pipeline Programs
6
Companies
12
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
2
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
12 programs
2
1
DescovyPhase 41 trial
Immediate Intervention ArmPhase 2/31 trial
Immediate Intervention ArmPhase 2/3
A chatbot designed to promote PrEP awareness and uptake for Black MSMN/A
A chatbot designed to promote PrEP awareness and uptake for Black MSMN/A1 trial
+7 more programs
Active Trials
NCT05968755Not Yet Recruiting145Est. Jul 2026
NCT05690815Active Not Recruiting816Est. Nov 2024
NCT04418037Completed16Est. Dec 2021
+5 more trials
Orion Biotechnology
1 program
1
OB-002Phase 11 trial
Active Trials
NCT04791007CompletedEst. Aug 2020
BRAND
BRANDGermany - Wertheim
1 program
1
Q-GriffithsinPhase 11 trial
Active Trials
NCT04032717Terminated18Est. Feb 2021
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Couple User Preferences in Dual Purpose Prevention ProductsN/A1 trial
Active Trials
NCT04023799CompletedEst. Nov 2020
M&
Merck & Co.RAHWAY, NJ
1 program
Individualized FeedbackN/A1 trial
Active Trials
NCT05165745Recruiting175Est. Oct 2026
Stuart Therapeutics
1 program
Value Affirmation and Future Selves CombinationN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Gilead SciencesDescovy
Gilead SciencesDigital Health Feedback System
Gilead SciencesImmediate Intervention Arm
Orion BiotechnologyOB-002
BRANDQ-Griffithsin
Gilead SciencesA chatbot designed to promote PrEP awareness and uptake for Black MSM
Gilead SciencesI'm Fully Empowered for Her
Gilead SciencesGain framing plus demographically targeted photos
Gilead SciencesDescovy
Merck & Co.Individualized Feedback
Allergy TherapeuticsCouple User Preferences in Dual Purpose Prevention Products
Gilead SciencesDigital Health Feedback System

Clinical Trials (12)

Total enrollment: 1,715 patients across 12 trials

NCT05528653Gilead SciencesDescovy

Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"

Start: Jul 2022Est. completion: Mar 202575 patients
Phase 4Completed
NCT04418037Gilead SciencesDigital Health Feedback System

DHFS for Medication Adherence Support During Hospital Admissions for Person Living With HIV

Start: May 2019Est. completion: Dec 202116 patients
Phase 4Completed
NCT04742491Gilead SciencesImmediate Intervention Arm

Pre-Exposure Prophylaxis for Transgender Women in the US and South America

Start: Mar 2021Est. completion: Aug 2024304 patients
Phase 2/3Completed
NCT04791007Orion BiotechnologyOB-002

OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults

Start: Oct 2019Est. completion: Aug 2020
Phase 1Completed
NCT04032717BRANDQ-Griffithsin

Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)

Start: Jul 2019Est. completion: Feb 202118 patients
Phase 1Terminated
NCT05968755Gilead SciencesA chatbot designed to promote PrEP awareness and uptake for Black MSM

Leveraging Chatbot to Improve PrEP in the Southern United States

Start: Mar 2026Est. completion: Jul 2026145 patients
N/ANot Yet Recruiting
NCT05644834Gilead SciencesI'm Fully Empowered for Her

Pilot Mobile Medical Unit Study for I'm Fully Empowered4Her

Start: Apr 2023Est. completion: Dec 202335 patients
N/ACompleted
NCT05087927Gilead SciencesGain framing plus demographically targeted photos

Study for IFE4PrEP Intervention on PrEP Uptake by Southern African American Women

Start: Apr 2023Est. completion: Mar 202431 patients
N/ACompleted
NCT05690815Gilead SciencesDescovy

Express Testing and Same-day Initiation of PrEP Study

Start: Jan 2023Est. completion: Nov 2024816 patients
N/AActive Not Recruiting
NCT05165745Merck & Co.Individualized Feedback

Stick2PrEP Cisgender Women and Trans Individuals

Start: Oct 2021Est. completion: Oct 2026175 patients
N/ARecruiting
NCT04023799Allergy TherapeuticsCouple User Preferences in Dual Purpose Prevention Products

Couple User Preferences in Dual Purpose Prevention Products

Start: Jan 2020Est. completion: Nov 2020
N/ACompleted
NCT03693040Gilead SciencesDigital Health Feedback System

Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)

Start: Dec 2016Est. completion: Dec 2022100 patients
N/AUnknown

Related Jobs in Infectious Diseases

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
8h ago
$179K - $237K/yr

Executive Director, Global Medical Expert HIV Prevention - GMA Virology & Inflammation

Gilead Sciences
United States - Field
20h ago
$317K - $411K/yr

Sr. Engineer, Process Systems (Contract)

VaxCyte
Visp, Valais, Switzerland
23h ago

Contract Senior Research Associate, Protein Science

Keros Therapeutics
Lexington, Massachusetts, United States
Yesterday

Director, Health Economics & Outcomes Research (HEOR)

VaxCyte
San Carlos, California, United States
Yesterday
$242K - $282K/yr

Senior Manager, Contract Account Performance Specialist, Contract Strategy

Pfizer
Remote
Yesterday
$124K - $207K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,715 patients
6 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)